Reviva Pharmaceuticals Holdings, Inc.
News
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Globe Newswire Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia Additional vocal...\n more…
Maxim Group Reaffirms Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)
TipRanks Financial Blog In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Reviva Pharmaceuticals Holdings (RVPH - Research Report...\n more…
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire CUPERTINO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ( Reviva or the Company ), a late-stage pharmaceutical company developing therapies that...\n more…
Reviva Pharmaceuticals Holdings, Inc. to Post FY2024 Earnings of ($0.91) Per Share, Zacks Small Cap Forecasts (NASDAQ:RVPH)
Zolmax Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Zacks Small Cap upped their FY2024 EPS estimates for Reviva Pharmaceuticals in a research note issued on Monday...\n more…
Reviva Pharmaceuticals Holdings, Inc. to Post FY2024 Earnings of ($0.91) Per Share, Zacks Small Cap Forecasts (NASDAQ:RVPH)
Ticker Report Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Zacks Small Cap upped their FY2024 EPS estimates for Reviva Pharmaceuticals in a research note issued on Monday, August...\n more…
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
Globe Newswire CUPERTINO, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ( Reviva or the Company ), a late-stage pharmaceutical company developing therapies that...\n more…